NASDAQ:IRMD Iradimed (IRMD) Stock Price, News & Analysis → Only a fool would buy Nvidia today… (From Porter & Company) (Ad) Free IRMD Stock Alerts $43.99 +0.62 (+1.43%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$43.15▼$44.6450-Day Range$41.17▼$46.7652-Week Range$36.12▼$51.04Volume64,163 shsAverage Volume56,165 shsMarket Capitalization$556.91 millionP/E Ratio32.35Dividend Yield1.36%Price Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Iradimed alerts: Email Address Iradimed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.4% Upside$60.00 Price TargetShort InterestHealthy1.42% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-0.85Upright™ Environmental ScoreNews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.82 out of 5 starsMedical Sector35th out of 938 stocksSurgical & Medical Instruments Industry6th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingIradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.00, Iradimed has a forecasted upside of 36.4% from its current price of $43.99.Amount of Analyst CoverageIradimed has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.42% of the float of Iradimed has been sold short.Short Interest Ratio / Days to CoverIradimed has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iradimed has recently increased by 11.01%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldIradimed pays a meaningful dividend of 1.41%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthIradimed does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Iradimed is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIradimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for Iradimed is -0.85. Previous Next 1.9 News and Social Media Coverage News SentimentIradimed has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Iradimed this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Iradimed to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iradimed insiders have not sold or bought any company stock.Percentage Held by Insiders42.60% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.34% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Iradimed is 32.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Iradimed is 32.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 250.30.Price to Book Value per Share RatioIradimed has a P/B Ratio of 7.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Iradimed Stock (NASDAQ:IRMD)IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Read More IRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRMD Stock News HeadlinesMarch 20, 2024 | americanbankingnews.comIRadimed Co. (NASDAQ:IRMD) Short Interest Up 5.7% in FebruaryMarch 15, 2024 | finance.yahoo.comIRMD Jul 2024 60.000 callMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 13, 2024 | globenewswire.comIRADIMED CORPORATION To Participate at the 36th Annual Roth ConferenceMarch 13, 2024 | wsj.comiRadimed Corp.February 26, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)February 26, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)February 19, 2024 | finance.yahoo.comShould You Invest in IRadimed Corporation (IRMD)?March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 17, 2024 | finance.yahoo.comIRMD Mar 2024 45.000 putFebruary 17, 2024 | finance.yahoo.comIRMD Mar 2024 40.000 callFebruary 15, 2024 | finance.yahoo.comIRMD Feb 2024 44.520 callFebruary 11, 2024 | finance.yahoo.comInstitutional investors own a significant stake of 39% in IRadimed Corporation (NASDAQ:IRMD)February 9, 2024 | finance.yahoo.comIRadimed Corporation (NASDAQ:IRMD) Q4 2023 Earnings Call TranscriptFebruary 8, 2024 | finance.yahoo.comiRadimed Corp (IRMD) Reports Record Revenues and Robust Earnings Growth in Q4 and Full-Year 2023February 8, 2024 | markets.businessinsider.comIRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial ResultsFebruary 8, 2024 | washingtonpost.comIRadimed: Q4 Earnings SnapshotFebruary 7, 2024 | benzinga.comiRadimed's Earnings OutlookFebruary 7, 2024 | msn.comiRadimed Q4 2023 Earnings PreviewFebruary 7, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on Iradimed (IRMD)February 1, 2024 | finance.yahoo.comIRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.February 1, 2024 | seekingalpha.comIRadimed: Caution On The Valuation Of This Excellent CompanyJanuary 9, 2024 | finance.yahoo.comIRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 RevenueJanuary 7, 2024 | finance.yahoo.comWhat Is IRadimed Corporation's (NASDAQ:IRMD) Share Price Doing?January 2, 2024 | finance.yahoo.comIRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | benzinga.comWednesday Is Your Last Chance To Buy iRadimed Before The Dividend PayoutDecember 12, 2023 | marketwatch.comIRadimed Initiates 15c Quarterly Dividend, Declares Special Dividend of 48cSee More Headlines Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 1/12 Dividend12/21/2023Dividend Payable1/12/2024Last Earnings2/08/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:IRMD CUSIPN/A CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees148Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+36.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.36 Trailing P/E Ratio32.35 Forward P/E RatioN/A P/E GrowthN/ANet Income$17.19 million Net Margins26.22% Pretax Margin33.16% Return on Equity24.62% Return on Assets20.43% Debt Debt-to-Equity RatioN/A Current Ratio4.65 Quick Ratio3.87 Sales & Book Value Annual Sales$65.56 million Price / Sales8.49 Cash Flow$1.47 per share Price / Cash Flow29.91 Book Value$5.66 per share Price / Book7.77Miscellaneous Outstanding Shares12,660,000Free Float7,269,000Market Cap$556.91 million OptionableOptionable Beta0.82 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Roger E. Susi (Age 71)Founder, Chairman, CEO & President Comp: $586.04kMr. John F. Glenn (Age 62)CFO & Corporate Secretary Comp: $411.79kMr. Randy WaddellVice President of Worldwide Sales & MarketingMr. Steve KachelmeyerVice President of Regulatory Affairs & Quality AssuranceMr. Lynn NeuhardtVice President of Research & DevelopmentMr. Chris WilliamsonExecutive Vice President of Continuous Improvement & Information TechnologyMr. Matt GarnerControllerMore ExecutivesKey CompetitorsBeauty HealthNASDAQ:SKINOrthofix MedicalNASDAQ:OFIXNevroNYSE:NVROOrthoPediatricsNASDAQ:KIDSOraSure TechnologiesNASDAQ:OSURView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 14,724 shares on 3/11/2024Ownership: 3.371%Goldman Sachs Group Inc.Sold 1,993 shares on 3/1/2024Ownership: 0.429%Cim LLCBought 9,458 shares on 2/23/2024Ownership: 0.075%Legal & General Group PlcBought 249 shares on 2/15/2024Ownership: 0.072%West Tower Group LLCBought 1,204 shares on 2/15/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions IRMD Stock Analysis - Frequently Asked Questions Should I buy or sell Iradimed stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares. View IRMD analyst ratings or view top-rated stocks. What is Iradimed's stock price target for 2024? 1 analysts have issued 12 month target prices for Iradimed's stock. Their IRMD share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 36.4% from the stock's current price. View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts. How have IRMD shares performed in 2024? Iradimed's stock was trading at $47.47 at the beginning of the year. Since then, IRMD shares have decreased by 7.3% and is now trading at $43.99. View the best growth stocks for 2024 here. Are investors shorting Iradimed? Iradimed saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 112,900 shares, an increase of 11.0% from the February 29th total of 101,700 shares. Based on an average daily volume of 54,200 shares, the days-to-cover ratio is currently 2.1 days. Approximately 1.4% of the shares of the company are sold short. View Iradimed's Short Interest. When is Iradimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our IRMD earnings forecast. How were Iradimed's earnings last quarter? Iradimed Corporation (NASDAQ:IRMD) announced its earnings results on Thursday, February, 8th. The medical equipment provider reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.37 by $0.01. The medical equipment provider earned $17.45 million during the quarter. Iradimed had a net margin of 26.22% and a trailing twelve-month return on equity of 24.62%. How often does Iradimed pay dividends? What is the dividend yield for Iradimed? Iradimed announced a -- dividend on Tuesday, December 12th. Investors of record on Friday, December 22nd will be given a dividend of $0.15 per share on Friday, January 12th. The ex-dividend date of this dividend is Thursday, December 21st. Read our dividend analysis for IRMD. Is Iradimed a good dividend stock? Iradimed (NASDAQ:IRMD) pays an annual dividend of $0.60 per share and currently has a dividend yield of 1.41%. The dividend payout ratio is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for IRMD. What ETF holds Iradimed's stock? Ballast Small/Mid Cap ETF holds 19,404 shares of IRMD stock, representing 0.98% of its portfolio. What guidance has Iradimed issued on next quarter's earnings? Iradimed issued an update on its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 0.330-0.350 for the period, compared to the consensus estimate of 0.410. The company issued revenue guidance of $17.0 million-$17.3 million, compared to the consensus revenue estimate of $17.6 million. What other stocks do shareholders of Iradimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR). Who are Iradimed's major shareholders? Iradimed's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.39%), Vanguard Group Inc. (3.37%), RK Capital Management LLC (2.70%), Ranger Investment Management L.P. (1.77%), Russell Investments Group Ltd. (1.68%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi. View institutional ownership trends. How do I buy shares of Iradimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IRMD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iradimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.